Oncology Today with Dr Neil Love

Research To Practice
Research To Practice

Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.

  1. 3h ago

    Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

    Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics: Introduction (0:00)Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24) CME information and select publications

  2. 1d ago

    EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

    Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (00:00)Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27)EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08)Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16)Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08)Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46) CME information and select publications

  3. 2d ago

    Endometrial Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

    Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Introduction (00:00)Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50)Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15)Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41) CME information and select publications

  4. 5d ago

    HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

    Featuring an interview with Prof Dr Sibylle Loibl, including the following topics: Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03) CME information and select publications

  5. 6d ago

    For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress

    Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30) CME information and select publications

  6. Jul 15

    Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

    Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics: Introduction (00:00)Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39) CME information and select publications

  7. Jul 14

    HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review

    Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics: Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00)Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07)Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50) CME information and select publications

  8. Jul 13

    Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

    Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics: Introduction: ODAC — April 30, 2026 (00:00)Adjuvant CDK4/6 Inhibitors (13:03)Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)Premenopausal Patients (30:52)Duration of Adjuvant Endocrine Treatment (38:44)Genomic Predictors of Chemotherapy Benefit (47:19)Neoadjuvant Treatment (55:13) CME information and select publications

See All (459)

Ratings & Reviews

4.8
out of 5
61 Ratings

About

Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.

Information

More From Research To Practice

You Might Also Like